Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone.
Mukhtar
R
R
Department of Endocrinology, Diabetes & Metabolism, Royal United Hospital, Bath, UK.
Reckless
J P D
JP
D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D019317:Evidence-Based Medicine; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone